During the corresponding time, Can Fite Biopharma Ltd saw a revenue deteriorated by -39.91 % year on year, While revenue at the Can Fite Biopharma Ltd 's corporate clients
Can Fite Biopharma Ltd's Comment on Sales, Marketing and Customers
The text outlines the regulatory process for marketing a new drug in the United States. It details the necessary steps, including conducting preclinical tests, submitting an Investigational New Drug (IND) application, performing clinical trials, submitting a New Drug Application (NDA), undergoing FDA reviews, and adhering to post-approval compliance requirements.
In a significant move that could reshape the landscape of rare disease treatment, Can-Fite Biopharma Ltd. has announced plans to initiate a Phase II clinical trial aimed at addressing Lowe Syndrome, a rare genetic disorder primarily affecting the eyes and brain. The study will focus on the therapeutic potential of Piclidenoson, an innovative candidate that may offer a new lease on life for those affected by this debilitating condition. Understanding Lowe Syndrome and the Need for Novel TreatmentsLowe Syndrome is characterized by a series of severe symptoms, including ocular anomalies and cognitive impairments, resulting from mutations in the OCRL gene. The rarity of the disease translates into a limited pool...
Can-Fite BioPharma Secures $5 Million Through Warrant Exercise: A Strategic Move for Oncology and Inflammatory Disease Drug Development RAMAT GAN, Israel August 8, 2024 Can-Fite BioPharma Ltd., a growing player in the biotechnology sector focused on developing innovative treatments for oncological and inflammatory diseases, has announced a significant financial maneuver expected to bolster its ongoing research and development efforts. The company revealed it has entered into a definitive agreement to exercise outstanding warrants, generating approximately $5 million in gross proceeds. This move is pivotal as Can-Fite aims to enhance its portfolio of proprietary small molecule drugs designed to address ...
Can Fite Biopharma Ltd’s Comment on Sales, Marketing and Customers
The text outlines the regulatory process for marketing a new drug in the United States. It details the necessary steps, including conducting preclinical tests, submitting an Investigational New Drug (IND) application, performing clinical trials, submitting a New Drug Application (NDA), undergoing FDA reviews, and adhering to post-approval compliance requirements.
Sources:
Can fite Biopharma Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Can fite Biopharma Ltd’s corporate clients.
For your research, we’ve provided 9 tables on Can fite Biopharma Ltd corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
